$219 Million is the total value of Eversept Partners, LP's 72 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 191.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QCP | Buy | QUALITY CARE PPTYS INC | $23,103,461 | +15.4% | 1,074,080 | +4.2% | 10.57% | +13.6% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $15,327,230 | +34.0% | 226,902 | +7.6% | 7.01% | +32.0% |
| RDUS | Buy | RADIUS HEALTH INC | $13,809,082 | +15.1% | 468,581 | +40.4% | 6.32% | +13.4% |
| GSK | Buy | GLAXOSMITHKLINE PLCsponsored adr | $10,315,317 | +15.3% | 252,584 | +11.5% | 4.72% | +13.5% |
| SNY | Buy | SANOFIsponsored adr | $8,521,010 | +54.1% | 212,972 | +54.4% | 3.90% | +51.8% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $7,937,009 | +112.8% | 84,257 | +83.2% | 3.63% | +109.6% |
| TLGT | Buy | TELIGENT INC NEW | $7,307,859 | +40.3% | 2,112,098 | +36.2% | 3.34% | +38.2% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $6,793,559 | +75.7% | 43,401 | +80.8% | 3.11% | +73.1% |
| ZGNX | New | ZOGENIX INCput | $5,449,860 | – | 123,300 | +100.0% | 2.49% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $5,287,200 | – | 40,000 | +100.0% | 2.42% | – |
| ATHN | New | ATHENAHEALTH INC | $2,546,240 | – | 16,000 | +100.0% | 1.16% | – |
| TSRO | Buy | TESARO INC | $2,335,698 | -20.7% | 52,523 | +1.9% | 1.07% | -21.9% |
| ANAB | New | ANAPTYSBIO INC | $2,318,319 | – | 32,634 | +100.0% | 1.06% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $2,164,690 | – | 98,395 | +100.0% | 0.99% | – |
| ARQL | New | ARQULE INC | $2,069,990 | – | 374,320 | +100.0% | 0.95% | – |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $1,999,192 | +27.1% | 30,054 | +24.9% | 0.91% | +25.0% |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,437,228 | – | 107,096 | +100.0% | 0.66% | – |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $1,421,400 | +88.9% | 460,000 | +84.0% | 0.65% | +85.7% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $1,415,105 | -9.3% | 23,924 | +4.4% | 0.65% | -10.8% |
| TNDM | New | TANDEM DIABETES CARE INC | $1,349,826 | – | 61,300 | +100.0% | 0.62% | – |
| IMMU | New | IMMUNOMEDICS INC | $1,301,850 | – | 55,000 | +100.0% | 0.60% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $1,258,605 | – | 4,500 | +100.0% | 0.58% | – |
| AKRXQ | New | AKORN INC | $1,161,300 | – | 70,000 | +100.0% | 0.53% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $1,041,250 | – | 85,000 | +100.0% | 0.48% | – |
| CLLS | New | CELLECTIS S Asponsored ads | $848,700 | – | 30,000 | +100.0% | 0.39% | – |
| VCEL | New | VERICEL CORP | $725,919 | – | 74,837 | +100.0% | 0.33% | – |
| IIN | New | INTRICON CORP | $483,600 | – | 12,000 | +100.0% | 0.22% | – |
| ZGNX | New | ZOGENIX INCcall | $442,000 | – | 10,000 | +100.0% | 0.20% | – |
| QCP | New | QUALITY CARE PROPERTIES ORDcall | $430,200 | – | 20,000 | +100.0% | 0.20% | – |
| MODN | New | MODEL N INC | $417,775 | – | 22,461 | +100.0% | 0.19% | – |
| CDMO | New | AVID BIOSERVICES INC | $393,576 | – | 100,402 | +100.0% | 0.18% | – |
| CYAD | New | CELYAD SAadr | $381,634 | – | 12,840 | +100.0% | 0.18% | – |
| CFMS | New | CONFORMIS INC | $158,564 | – | 126,851 | +100.0% | 0.07% | – |
| GLMD | New | GALMED PHARMACEUTICALS LTD | $119,000 | – | 10,000 | +100.0% | 0.05% | – |
| QCP | New | QUALITY CARE PROPERTIES ORDput | $38,718 | – | 1,800 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMARIN CORP PLC | 21 | Q3 2023 | 12.5% |
| DANAHER CORPORATION | 21 | Q3 2023 | 8.1% |
| AFFIMED N V | 20 | Q3 2023 | 0.9% |
| ARGENX SE | 19 | Q3 2023 | 2.0% |
| GSK PLC | 18 | Q2 2022 | 13.1% |
| ASCENDIS PHARMA A/S | 18 | Q1 2022 | 7.7% |
| SANOFI | 18 | Q4 2022 | 7.2% |
| ENSIGN GROUP INC | 18 | Q1 2022 | 8.6% |
| CENTENE CORP DEL | 18 | Q3 2023 | 1.5% |
| ZOGENIX INC | 17 | Q4 2021 | 12.4% |
View Eversept Partners, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cabaletta Bio, Inc. | February 14, 2023 | 282,874 | 1.0% |
| Teligent, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| Teligent, Inc. | February 14, 2020 | 4,501,799 | 8.4% |
View Eversept Partners, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
View Eversept Partners, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.